Zevra Therapeutics Inc (NAS:ZVRA)
$ 8.11 -0.42 (-4.92%) Market Cap: 432.88 Mil Enterprise Value: 403.43 Mil PE Ratio: 0 PB Ratio: 6.19 GF Score: 40/100
Back to the Transcripts List

Q3 2024 Zevra Therapeutics Inc Earnings Call Transcript

Nov 12, 2024 / 09:30 PM GMT
Release Date Price: $8.57 (-4.35%)

Key Points

Positve
  • Zevra Therapeutics Inc (ZVRA) successfully launched Myle, the first FDA-approved therapy for Niemann-Pick disease type C, with 90 prescription enrollment forms submitted by October 31st.
  • The company received a rare pediatric disease priority review voucher (PRV) with the approval of Myle, which they plan to monetize for non-dilutive capital.
  • Zevra Therapeutics Inc (ZVRA) completed an end of phase two meeting with the FDA for KP1077, receiving clear direction for a phase three path forward.
  • The company has a strategic plan for 2025 focusing on commercial excellence, pipeline and innovation, talent and culture, and corporate foundation.
  • Zevra Therapeutics Inc (ZVRA) completed a public offering, raising approximately $64.5 million, extending their cash runway into 2027.
Negative
  • The launch of Aprova, a treatment for urea cycle disorders, is underperforming with only three prescription enrollment forms received in the third quarter.
  • Zevra Therapeutics Inc (ZVRA) reported a net loss of $33.2 million for the third quarter, a significant increase from the previous year.
  • The company decided to discontinue in-house pro-drug discovery activities and close facilities in Iowa and Virginia, indicating a shift in strategy.
  • There are challenges in raising patient awareness and overcoming reimbursement hurdles for Aprova in the urea cycle disorder market.
  • Zevra Therapeutics Inc (ZVRA) has halted some development activities, including Osanit, as part of their pipeline review.


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

ZVRA.OQ - Zevra Therapeutics Inc
Q3 2024 Zevra Therapeutics Inc Earnings Call
Nov 12, 2024 / 09:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------

We stand by. We're about to begin.

Good afternoon and thank you for joining Zebra Therapeutics third quarter, financial results and corporate update conference call. Today's call is being recorded and will be available via the investor relations section of the company's website. Later today, the host for today's call is Nicole Ashner. Zebra's Vice President of Investor Relations and Corporate Communications. Nicole. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you and welcome to those who are joining us today. We will provide an overview
Already have an account? Log in
Get the full story
Start 7-Day Free Trial
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot
Research Tools
All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board
Product
Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App 中文
Education
Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation
Company
About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program
Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey
Follow Us
download GuruFocus on Apple store download GuruFocus on Google Play
Disclaimers
GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.
© 2004-2025 GuruFocus.com, LLC. All Rights Reserved.